Search

Displaying results 1501 - 1510 of 4207 in total
  1. Drug

    Arimoclomol

    go.drugbank.com/drugs/DB05025
    Approved

    [L51384] Arimoclomol was approved by the FDA on September 20, 2024, making it the first treatment for Niemann-Pick disease, type C (NPC).

  2. Drug

    Copper gluconate

    go.drugbank.com/drugs/DB11246
    ApprovedInvestigational

    It is prepared by the reaction of gluconic acid solutions with cupric oxide or basic cupric carbonate. … According to the good manufacturing or feeding practice by the FDA, copper gluconate is used as a nutrient or dietary supplement and is generally recognized as safe for use at a level not exceeding 0.005

  3. Drug

    Milsaperidone

    go.drugbank.com/drugs/DB24348
    ApprovedInvestigational

    [L56056] Atypical antipsychotic agents work by blocking the D2 dopamine and serotonin receptor signalling pathways. … [L56056] On February 20, 2026, milsaperidone was approved by the FDA for the treatment of Bipolar I Disorder and schizophrenia.[L56059]

  4. Drug

    Magnesium carbonate

    go.drugbank.com/drugs/DB09481
    Approved

    Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label].

  5. Drug

    Formestane

    go.drugbank.com/drugs/DB08905
    ApprovedWithdrawn

    It is listed as a prohibited substance by the World Anti-Doping Agency for use in athletes. … Formestane has poor oral bioavailability, and thus must be administered fortnightly (bi-weekly) by intramuscular injection.

  6. Drug

    Fenfluramine

    go.drugbank.com/drugs/DB00574
    ApprovedIllicitInvestigationalWithdrawn

    It is currently sold under the name FINTEPLA® by Zogenix INC.[L14522] … It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression.

  7. Drug

    Janssen COVID-19 Vaccine

    go.drugbank.com/drugs/DB15857
    ApprovedInvestigational

    The Janssen COVID-19 vaccine (Ad26.COV2.S) is a recombinant vaccine that contains an adenovirus serotype 26 (Ad26) vector expressing a stabilized SARS-CoV-2 spike protein. The vaccine was created in collaboration with Johnson and Johnson...

  8. Drug

    AstraZeneca COVID-19 Vaccine

    go.drugbank.com/drugs/DB15656
    ApprovedInvestigational

    clots in association with thrombocytopenia - a causal link with the vaccine has not been proven, but is possible and requires further analysis. … Upon review, the European Medicines Agency (EMA) determined that the vaccine was not associated with a higher overall risk of blood clots, but that it may be associated with very rare instances of blood

  9. Drug

    Fitusiran

    go.drugbank.com/drugs/DB15002
    ApprovedInvestigational

    [L52865] By causing the degradation of antithrombin mRNA and promoting thrombin generation, fitusiran works to restore hemostasis in patients with hemophilia.[A273770] … [L52860] Fitusiran was first approved by the FDA on March 28, 2025, as routine prophylaxis therapy to prevent or reduce the frequency of bleeding episodes associated with hemophilia A or B.

  10. Drug

    Upadacitinib

    go.drugbank.com/drugs/DB15091
    ApprovedInvestigational

    It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. … [L10896] In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration.